Reverse HER2-negative Immune Resistant Breast Cancer
Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open-label study evaluating the efficacy and safety of combined treatment (retinoic acid) with immune checkpoint inhibitor in HER2-negative breast cancer patients who progressed during previous immune checkpoint inhibitors.